What is the best treatment for hypertrophic cardiomyopathy

1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation 1995;92:785–9 [PubMed] [Google Scholar]

2. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989;321:1372–8 [PubMed] [Google Scholar]

3. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114:216–25 [PubMed] [Google Scholar]

4. Marian AJ. Phenotypic plasticity of sarcomeric protein mutations. J Am Coll Cardiol 2007;49:2427–9 [PMC free article] [PubMed] [Google Scholar]

5. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J 2011;32:1161–70 [PubMed] [Google Scholar]

6. Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112:1332–8 [PubMed] [Google Scholar]

7. Yamaguchi H, Nishiyama S, Nakanishi S, et al. Electrocardiographic, echocardiographic and ventriculographic characterization of hypertrophic non-obstructive cardiomyopathy. Eur Heart J 1983;4 Suppl F:105–19 [PubMed] [Google Scholar]

8. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:638–45 [PubMed] [Google Scholar]

9. Sakamoto T, Tei C, Murayama M, et al. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J 1976;17:611–29 [PubMed] [Google Scholar]

10. Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of african/afro-caribbean origin. Eur Heart J 2011;32:2304–13 [PubMed] [Google Scholar]

11. Ingles J, Doolan A, Chiu C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005;42:e59. [PMC free article] [PubMed] [Google Scholar]

12. Gupta RM, Weiner RB, Baggish AL, et al. Still a kid at heart: hypertrophic cardiomyopathy in the elderly. Circulation 2011; 124:857–63 [PubMed] [Google Scholar]

13. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;42:1687–713 [PubMed] [Google Scholar]

14. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699–708 [PubMed] [Google Scholar]

15. Kubo T, Gimeno JR, Bahl A, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 2007;49:2419–26 [PubMed] [Google Scholar]

16. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)–phenotype negative (−) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011;107:604–8 [PubMed] [Google Scholar]

17. Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of The European Society of Cardiology. Eur Heart J 2005;26:1422–45 [PubMed] [Google Scholar]

18. Pelliccia A, Maron BJ, Spataro A, et al. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes. N Engl J Med 1991;324:295–301 [PubMed] [Google Scholar]

19. Basavarajaiah S, Boraita A, Whyte G, et al. Ethnic differences in left ventricular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;51:2256–62 [PubMed] [Google Scholar]

20. Wu JC, Ho CY, Skali H, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010;31:1088–97 [PMC free article] [PubMed] [Google Scholar]

21. Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich’s ataxia: a clinical study of 75 patients. J Am Coll Cardiol 1986;7:1370–8 [PubMed] [Google Scholar]

22. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746–59 [PubMed] [Google Scholar]

23. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active amp kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357–62 [PMC free article] [PubMed] [Google Scholar]

24. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 2009;374:1986–96 [PubMed] [Google Scholar]

25. Moon JC, McKenna WJ. The emerging role of cardiovascular magnetic resonance in refining the diagnosis of hypertrophic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2009;6:166–7 [PubMed] [Google Scholar]

26. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295–303 [PubMed] [Google Scholar]

27. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular out-Tow tract obstruction. Circulation 2006;114:2232–9 [PubMed] [Google Scholar]

28. Maron BJ. Hypertrophic cardiomyopathy. JAMA 2002;287: 1308–20 [PubMed] [Google Scholar]

29. Spoladore R, Maron MS, D’Amato R, et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur Heart J 2012;33:1724–33 [PubMed] [Google Scholar]

30. Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. J Am Coll Cardiol 2011;58:e212–60 [PubMed] [Google Scholar]

31. Ball W, Ivanov J, Rakowski H, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2011;58:2313–21 [PubMed] [Google Scholar]

32. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985;72:853–64 [PubMed] [Google Scholar]

33. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation 1967;35:847–51 [PubMed] [Google Scholar]

34. Cohn LH, Trehan H, Collins JJ. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1992;70:657–60 [PubMed] [Google Scholar]

35. Dearani JA, Ommen SR, Gersh BJ, et al. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy — the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007; 4:503–12 [PubMed] [Google Scholar]

36. Elliott PM, Gimeno Blanes JR, Mahon NG, et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420–4 [PubMed] [Google Scholar]

37. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212–8 [PubMed] [Google Scholar]

38. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981;64:437–41 [PubMed] [Google Scholar]

39. Fernandes VL, Nielsen C, Nagueh SF, et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv 2008;1: 561–70 [PubMed] [Google Scholar]

40. Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death prediction and prevention: report from a national heart, lung, and blood institute and heart rhythm society workshop. Circulation 2010;122:2335–48 [PMC free article] [PubMed] [Google Scholar]

41. Harrison DC, Braunwald E, Glick G, et al. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation 1964;29:84–98 [PubMed] [Google Scholar]

42. Jassal DSD, Neilan TGT, Fifer MAM, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J 2006;27:1805–10 [PubMed] [Google Scholar]

43. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997;18:1249–56 [PubMed] [Google Scholar]

44. Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 2008; 97:234–43 [PubMed] [Google Scholar]

45. Kwon DH, Kapadia SR, Tuzcu EM, et al. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc Interv 2008;1:432–8 [PubMed] [Google Scholar]

46. Lisboa LAF, Dallan LAO, Pomerantzeff PMA, et al. Long term results of septal myectomy in the treatment of obstructive hypertrophic cardiomyopathy. Rev Bras Cir Cardiovasc 2011; 26:86–92 [PubMed] [Google Scholar]

47. Lyne JC, Kilpatrick T, Duncan A, et al. Long-term follow-up of the first patients to undergo transcatheter alcohol septal ablation. Cardiology 2010;116:168–73 [PubMed] [Google Scholar]

48. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–64 [PubMed] [Google Scholar]

49. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 1999;99:2927–33 [PubMed] [Google Scholar]

50. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997;29:435–41 [PubMed] [Google Scholar]

51. Noseworthy PA, Rosenberg MA, Fifer MA, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009;104:128–32 [PubMed] [Google Scholar]

52. O’Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012;98:116–25 [PubMed] [Google Scholar]

53. Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517–24 [PubMed] [Google Scholar]

54. Olivotto I, Ommen SR, Maron MS, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 2007;50:831–4 [PubMed] [Google Scholar]

55. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982;307:997–9 [PubMed] [Google Scholar]

56. Pollick C. Disopyramide in hypertrophic cardiomyopathy II. Non-invasive assessment after oral administration. Am J Cardiol 1988; 62:1252–5 [PubMed] [Google Scholar]

57. Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg 2005;129:351–8 [PubMed] [Google Scholar]

58. Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 2011;75:28–37 [PubMed] [Google Scholar]

59. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996;111:586–94 [PubMed] [Google Scholar]

60. Rosing DR, Idänpään-Heikkilä U, Maron BJ, et al. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol 1985;55:185B–95B [PubMed] [Google Scholar]

61. Schulte HDH, Borisov KK, Gams EE, et al. Management of symptomatic hypertrophic obstructive cardiomyopathy — long-term results after surgical therapy. Thorac Cardiovasc Surg 1999; 47:213–8 [PubMed] [Google Scholar]

62. Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:1251–8 [PubMed] [Google Scholar]

63. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211–4 [PubMed] [Google Scholar]

64. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131–9 [PubMed] [Google Scholar]

65. Stenson RE, Flamm MD, Jr., Harrison DC, et al. Hypertophic subaortic stenosis clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol 1973;31:763–73 [PubMed] [Google Scholar]

66. ten Cate FJ, Soliman OI, Michels M, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 2010;3:362–9 [PubMed] [Google Scholar]

67. Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2007;49:350–7 [PubMed] [Google Scholar]

68. Welge D, Seggewiss H, Fassbender D, et al. Langzeitverlauf nach perkutaner septumablation bei hypertropher obstruktiver kardiomyopathie. Dtsch Med Wochenschr [article in German]. 2008;133:1949–54 [PubMed] [Google Scholar]

69. Shah JS, Esteban MTT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94:1288–94 [PubMed] [Google Scholar]

70. Sorajja P, Nishimura RA, Gersh BJ, et al. Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:234–41 [PubMed] [Google Scholar]

71. Jacoby D, McKenna WJ. Support for routine use of metabolic stress testing in hypertrophic cardiomyopathy. Am J Cardiol 2012; 109:1534–5 [PubMed] [Google Scholar]

72. Sorajja P, Allison T, Hayes C, et al. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2012;109:1494–8 [PubMed] [Google Scholar]

73. Elliott P, McKenna W. Hypertrophic cardiomyopathy. Lancet 2004;363:1881–91 [PubMed] [Google Scholar]

74. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur Heart J 2009;30:1080–7 [PubMed] [Google Scholar]

75. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol 2001;38:1994–2000 [PubMed] [Google Scholar]

76. Seggewiss H, Rigopoulos A, Welge D, et al. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2007;96:856–63 [PubMed] [Google Scholar]

77. Linde C, Gadler F, Kappenberger L, et al. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol 1999;83:903–7 [PubMed] [Google Scholar]

78. Rogers DP, Marazia S, Chow AW, et al. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 2008;10:507–13 [PubMed] [Google Scholar]

79. Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation 2011;124:40–7 [PubMed] [Google Scholar]

80. Yu EH, Omran AS, Wigle ED, et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol 2000; 36:2219–25 [PubMed] [Google Scholar]

81. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2011;57:e101–98 [PubMed] [Google Scholar]

82. Bos JM, Maron BJ, Ackerman MJ, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:1481–6 [PubMed] [Google Scholar]

83. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981;47:532–8 [PubMed] [Google Scholar]

84. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48:252–7 [PubMed] [Google Scholar]

85. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987–91 [PubMed] [Google Scholar]

86. Elliott PM, Sharma S, Varnava A, et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–601 [PubMed] [Google Scholar]

87. Monserrat L, Elliott PM, Gimeno JR, et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;42:873–9 [PubMed] [Google Scholar]

88. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933–41 [PubMed] [Google Scholar]

89. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405–12 [PubMed] [Google Scholar]

90. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369–74 [PubMed] [Google Scholar]

91. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009;119: 1703–10 [PubMed] [Google Scholar]

92. Maron BJ, Casey SA, Poliac LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999;281:650–5 [PubMed] [Google Scholar]

93. Topilsky Y, Pereira NL, Shah DK, et al. Left ventricular assist device therapy in patients with restrictive and hypertrophic cardiomyopathy. Circ Heart Fail 2011;4:266–75 [PubMed] [Google Scholar]

94. Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet 2002;11:2499–506 [PubMed] [Google Scholar]

95. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227–32 [PubMed] [Google Scholar]

What makes hypertrophic cardiomyopathy worse?

How can I reduce the thickness of my heart muscle?

Can you live a long life with hypertrophic cardiomyopathy?

What is the drug of choice for hypertrophic cardiomyopathy?